Supernus Pharmaceuticals Files 8-K

Ticker: SUPN · Form: 8-K · Filed: 2025-02-18T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, financial-reporting, sec-filing

Related Tickers: SUPN

TL;DR

SUPN filed an 8-K, looks like standard financial disclosures, nothing major.

AI Summary

On February 18, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No new financial figures or significant business updates were detailed in the provided excerpt.

Why It Matters

This filing indicates Supernus Pharmaceuticals is providing routine updates and disclosures to the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no indication of significant new risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals?

The primary purpose of this 8-K filing is to report Other Events and Financial Statements and Exhibits, as indicated by the filing's item information.

On what date was this 8-K report filed or effective?

The report was filed as of February 18, 2025, and the date of the earliest event reported is also February 18, 2025.

What is Supernus Pharmaceuticals, Inc.'s state of incorporation?

Supernus Pharmaceuticals, Inc. is incorporated in Delaware.

What is the principal executive office address for Supernus Pharmaceuticals, Inc.?

The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.

Does this filing indicate any specific new product launches or regulatory approvals?

The provided excerpt of the 8-K filing does not detail any specific new product launches or regulatory approvals; it focuses on 'Other Events' and 'Financial Statements and Exhibits'.

From the Filing

0001356576-25-000008.txt : 20250218 0001356576-25-000008.hdr.sgml : 20250218 20250218163535 ACCESSION NUMBER: 0001356576-25-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250218 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250218 DATE AS OF CHANGE: 20250218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 25635598 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 supn-20250218.htm 8-K supn-20250218 false 0001356576 0001356576 2025-02-18 2025-02-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 18, 2025   Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 9715 Key West Ave Rockville MD 20850 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: ( 301 ) 838-2500   Not Applicable (Former name or former address, if changed since last report.)   Securities registered pursuant to Section 12(b) of the Exchange Act Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Stock Market LLC Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01                                            Other Events. On February 18, 2025, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing topline results from the Phase 2b study of SPN-820 in adults with treatment-resistant depression. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01     &

View on Read The Filing